Sarah Verhoeff

97 [89Zr]Zr-DFO-durvalumab PET/CT before durvalumab treatment in R/M SCCHN patients CONCLUSION In conclusion, the PINCH study is the first to perform PD-L1 PET/CT in patients with R/M SCCHN. It has shown that [89Zr]Zr-DFO-durvalumab PET/CT imaging is feasible and safe. However, [89Zr]Zr-DFO-durvalumab uptake did not correlate to PD-L1 expression on a patient level and could not predict durvalumab treatment response. 5